Keybank National Association OH Sells 62,113 Shares of Lantheus Holdings, Inc. $LNTH

Keybank National Association OH lowered its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 10.8% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 514,722 shares of the medical equipment provider’s stock after selling 62,113 shares during the period. Keybank National Association OH owned about 0.74% of Lantheus worth $42,135,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. Whalen Wealth Management Inc. boosted its holdings in Lantheus by 35.2% in the 2nd quarter. Whalen Wealth Management Inc. now owns 5,872 shares of the medical equipment provider’s stock worth $481,000 after buying an additional 1,528 shares during the period. Ashton Thomas Private Wealth LLC boosted its holdings in Lantheus by 76.7% in the 2nd quarter. Ashton Thomas Private Wealth LLC now owns 12,680 shares of the medical equipment provider’s stock worth $1,038,000 after buying an additional 5,506 shares during the period. Envestnet Asset Management Inc. boosted its holdings in Lantheus by 18.8% in the 2nd quarter. Envestnet Asset Management Inc. now owns 147,582 shares of the medical equipment provider’s stock worth $12,081,000 after buying an additional 23,396 shares during the period. State of New Jersey Common Pension Fund D boosted its holdings in Lantheus by 1.0% in the 2nd quarter. State of New Jersey Common Pension Fund D now owns 25,197 shares of the medical equipment provider’s stock worth $2,063,000 after buying an additional 249 shares during the period. Finally, AlphaQuest LLC lifted its stake in Lantheus by 118.3% in the 2nd quarter. AlphaQuest LLC now owns 3,608 shares of the medical equipment provider’s stock worth $295,000 after purchasing an additional 1,955 shares in the last quarter. Institutional investors own 99.06% of the company’s stock.

Lantheus Stock Down 2.5%

Shares of NASDAQ LNTH opened at $55.88 on Thursday. The firm’s 50-day moving average price is $54.22 and its 200-day moving average price is $70.73. The company has a current ratio of 4.29, a quick ratio of 4.07 and a debt-to-equity ratio of 0.49. The stock has a market capitalization of $3.80 billion, a price-to-earnings ratio of 14.86 and a beta of 0.09. Lantheus Holdings, Inc. has a 12-month low of $47.25 and a 12-month high of $118.21.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share (EPS) for the quarter. The firm had revenue of $92.51 million for the quarter. Lantheus had a net margin of 17.82% and a return on equity of 34.06%. On average, equities research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have commented on LNTH shares. B. Riley dropped their price objective on shares of Lantheus from $109.00 to $84.00 and set a “buy” rating for the company in a report on Tuesday, September 16th. Weiss Ratings downgraded shares of Lantheus from a “hold (c-)” rating to a “sell (d+)” rating in a report on Saturday, October 25th. TD Cowen dropped their price objective on shares of Lantheus from $95.00 to $80.00 and set a “buy” rating for the company in a report on Monday, September 15th. JMP Securities dropped their price objective on shares of Lantheus from $112.00 to $73.00 and set a “market outperform” rating for the company in a report on Thursday, August 7th. Finally, William Blair reissued a “market perform” rating on shares of Lantheus in a report on Wednesday, July 16th. Four investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $74.50.

Insider Activity

In other news, insider Farallon Partners L. L C/Ca sold 3,365,000 shares of the company’s stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the sale, the insider directly owned 3,477,227 shares in the company, valued at approximately $195,246,296.05. This represents a 49.18% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Rajiv A. Patel sold 3,365,000 shares of the company’s stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the sale, the insider owned 3,477,227 shares in the company, valued at $195,246,296.05. This represents a 49.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 6,812,000 shares of company stock worth $382,427,380 over the last 90 days. Corporate insiders own 1.50% of the company’s stock.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.